Your browser doesn't support javascript.
loading
IL-23 stabilizes an effector Treg cell program in the tumor microenvironment.
Wertheimer, Tobias; Zwicky, Pascale; Rindlisbacher, Lukas; Sparano, Colin; Vermeer, Marijne; de Melo, Bruno Marcel Silva; Haftmann, Claudia; Rückert, Tamina; Sethi, Aakriti; Schärli, Stefanie; Huber, Anna; Ingelfinger, Florian; Xu, Caroline; Kim, Daehong; Häne, Philipp; Fonseca da Silva, André; Muschaweckh, Andreas; Nunez, Nicolas; Krishnarajah, Sinduya; Köhler, Natalie; Zeiser, Robert; Oukka, Mohamed; Korn, Thomas; Tugues, Sonia; Becher, Burkhard.
Afiliação
  • Wertheimer T; Department of Inflammation Research, Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland.
  • Zwicky P; Department of Inflammation Research, Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland.
  • Rindlisbacher L; Department of Inflammation Research, Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland.
  • Sparano C; Department of Inflammation Research, Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland.
  • Vermeer M; Department of Inflammation Research, Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland.
  • de Melo BMS; Department of Inflammation Research, Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland.
  • Haftmann C; Department of Pharmacology, Center for Research in Inflammatory Diseases, Ribeirao Preto Medical School, University of Sao Paulo, Sao Paulo, Brazil.
  • Rückert T; Department of Inflammation Research, Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland.
  • Sethi A; Department of Internal Medicine I, Hematology, Oncology, and Stem Cell Transplantation, Faculty of Medicine, Medical Centre, University of Freiburg, Freiburg, Germany.
  • Schärli S; Department of Inflammation Research, Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland.
  • Huber A; Department of Inflammation Research, Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland.
  • Ingelfinger F; Department of Inflammation Research, Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland.
  • Xu C; Department of Inflammation Research, Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland.
  • Kim D; Department of Inflammation Research, Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland.
  • Häne P; Department of Inflammation Research, Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland.
  • Fonseca da Silva A; Department of Inflammation Research, Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland.
  • Muschaweckh A; Department of Inflammation Research, Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland.
  • Nunez N; Institute for Experimental Neuroimmunology, Klinikum Rechts der Isar, Technical University of Munich, Munich, Germany.
  • Krishnarajah S; Department of Inflammation Research, Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland.
  • Köhler N; Department of Inflammation Research, Institute of Experimental Immunology, University of Zurich, Zurich, Switzerland.
  • Zeiser R; Department of Internal Medicine I, Hematology, Oncology, and Stem Cell Transplantation, Faculty of Medicine, Medical Centre, University of Freiburg, Freiburg, Germany.
  • Oukka M; Centre for Integrative Biological Signalling Studies (CIBSS), University of Freiburg, Freiburg, Germany.
  • Korn T; Department of Internal Medicine I, Hematology, Oncology, and Stem Cell Transplantation, Faculty of Medicine, Medical Centre, University of Freiburg, Freiburg, Germany.
  • Tugues S; Centre for Integrative Biological Signalling Studies (CIBSS), University of Freiburg, Freiburg, Germany.
  • Becher B; Department of Immunology, University of Washington, Seattle, WA, USA.
Nat Immunol ; 25(3): 512-524, 2024 Mar.
Article em En | MEDLINE | ID: mdl-38356059
ABSTRACT
Interleukin-23 (IL-23) is a proinflammatory cytokine mainly produced by myeloid cells that promotes tumor growth in various preclinical cancer models and correlates with adverse outcomes. However, as to how IL-23 fuels tumor growth is unclear. Here, we found tumor-associated macrophages to be the main source of IL-23 in mouse and human tumor microenvironments. Among IL-23-sensing cells, we identified a subset of tumor-infiltrating regulatory T (Treg) cells that display a highly suppressive phenotype across mouse and human tumors. The use of three preclinical models of solid cancer in combination with genetic ablation of Il23r in Treg cells revealed that they are responsible for the tumor-promoting effect of IL-23. Mechanistically, we found that IL-23 sensing represents a crucial signal driving the maintenance and stabilization of effector Treg cells involving the transcription factor Foxp3. Our data support that targeting the IL-23/IL-23R axis in cancer may represent a means of eliciting antitumor immunity.
Assuntos

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Interleucina-23 / Neoplasias Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Revista: Nat Immunol Assunto da revista: ALERGIA E IMUNOLOGIA Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Suíça

Texto completo: 1 Bases de dados: MEDLINE Assunto principal: Interleucina-23 / Neoplasias Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Revista: Nat Immunol Assunto da revista: ALERGIA E IMUNOLOGIA Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Suíça